Comparison of axitinib and sunitinib as first-line treatment for metastatic kidney cancer
This multicentre analysis of axitinib versus sunitinib used as first-line [...]
Nivolumab-ipilimumab combination delays the need for additional treatment in kidney cancer patients
A recent analysis of data from the phase 3 Checkmate-214 [...]
Promising avelumab plus axitinib data in renal cell carcinoma
The following OncLive interview with leading renal cell carcinoma (RCC) expert, Dr [...]
Tivozanib expected to be included in European clinical practice guidelines for advanced kidney cancer
Tivozanib is expected to be included as a first-line treatment [...]
ESMO 2018: Avelumab plus axitinib combination shows great promise as first-line treatment for advanced RCC
Results from the JAVELIN Renal 101 phase 3 study to [...]
Cabozantinib approved as a first-line treatment option for advanced kidney cancer on the NHS
Today, the National Institute for Health and Care Excellence (NICE) have recommended [...]
Negative EMA opinion for the ipilimumab/nivolumab combination
Yesterday it was announced that the combination of ipilimumab and [...]
First-line tivozanib approved for use in NHS Scotland
We are delighted that the Scottish Medicines Consortium (SMC), which reviews [...]
NICE set to decline first-line cabozantinib for advanced kidney cancer
The National Institute for Health and Care Excellence (NICE) have issued an [...]
European Medicines Agency approves first-line cabozantinib for advanced kidney cancer
Cabozantinib (Cabometyx) has been granted approval by the Committee for Medicinal [...]
